Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis.
Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.
Garske
Luke A
LA
Adult Cystic Fibrosis Unit and University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Bell
Scott C
SC
D000328:Adult; D000842:Ankle / Q000000981:diagnostic imaging; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010005:Osteoarthropathy, Secondary Hypertrophic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010010:Osteoclasts / Q000187:drug effects; D000077268:Pamidronate; D011859:Radiography
D004164:Diphosphonates; D000077268:Pamidronate